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The aberrant expression of microRNA-155 (miR-155),
which has emerged as having a significant impact on
the biological characteristics of lymphocytes, plays im-
portant roles in B-cell malignancies, such as diffuse
large B-cell lymphoma (DLBCL). DLBCL is themost com-
mon non–Hodgkin’s lymphoma in the adult popula-
tion, accounting for approximately 40% of newly diag-
nosed non–Hodgkin’s lymphoma cases globally. To
determine the specific function of miR-155, a quantita-
tive proteomics approach was applied to examine the
inhibitory effects of miR-155 on protein synthesis in
DLBCL cells. PIK3R1 (p85), a negative regulator of the
phosphatidylinositol 3-kinase (PI3K)–AKT pathway,
was identified as a direct target of miR-155. A luciferase
reporter was repressed through the direct interaction of
miR-155 and the p85 3=-untranslated region, and overex-
pression of miR-155 down-regulated both the transcrip-
tionand translationofp85. ThePI3K-AKTsignalingpath-
way was highly activated by the sustained overexpression
of miR-155 in DHL16 cells, whereas knockdown of miR-
155 in OCI-Ly3 cells diminished AKT activity. Taken to-
gether, our results reveal a novel target involved in miR-
155 biological characteristics andprovide amolecular link
between the overexpression ofmiR-155 and the activation
of PI3K-AKT in DLBCL. (Am J Pathol 2012, 181:26–33;
http://dx.doi.org/10.1016/j.ajpath.2012.03.013)
MicroRNAs (miRNAs) are single-stranded RNAs of ap-
proximately 21 to 23 nucleotides that negatively regulate
eukaryotic gene expression, mostly through base pairing
26with the 3=-untranslated region (UTR) of the target mRNA,
leading to either inhibition of protein translation or in-
creased mRNA degradation.1,2 Among miRNAs ex-
pressed by hematopoietic cells, miR-155 has emerged
as having a significant impact on the biological charac-
teristics of lymphocytes.3 Human miR-155 maps within
and is processed from an exon of a noncoding RNA
transcribed from the B-cell integration cluster (BIC) lo-
cated on chromosome 21.4 Normally, miR-155 is acti-
vated in response to B- or T-cell receptor engagement
and plays an important role in germinal center formation
and subsequent antibody production after antigen chal-
lenge.5,6 However, beyond its apparent contribution to
the humoral immune response, the need to properly reg-
ulate miR-155 levels is suggested by its dramatically
elevated expression in several types of human B-cell
lymphomas, such as primary mediastinal B-cell lym-
phoma, Burkitt’s lymphoma, and diffuse large B-cell lym-
phoma (DLBCL).7,8
DLBCL is the most common non–Hodgkin’s lymphoma
in the adult population and accounts for approximately
40% of newly diagnosed non–Hodgkin’s lymphoma
cases worldwide.9 It is a biologically and clinically heter-
ogeneous disease, in part because of the diversity of its
normal cell counterparts.10,11 Gene expression profiling
(GEP) has classified DLBCL into two main subcategories:
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B-cell-like (ABC) DLBCL.10,11 In general, ABC-DLBCL
has a significantly poorer survival than GCB-DLBCL.10,12
High miR-155 expression is more common in ABC-
DLBCL.13 However, the role of miR-155 overexpression
in lymphomagenesis is largely unknown.
It is believed that miRNAs have the potential to regu-
late at least 20% to 30% of all human genes.14 Recently,
large-scale approaches for studying the regulatory ef-
fects of miRNAs have emerged, which include genome-
wide computation of potential miRNA targets and exper-
imental identification of miRNA-perturbed proteomic
profiles.15 The stable isotope labeling (SIL)–based quan-
titative proteomics technique, combined with liquid chro-
matography and tandem mass spectrometry (LC-MS/
MS), has become the major approach for investigating
comprehensive profiles of protein expression. Overex-
pressing an miRNA in vitro causes a mostly modest (usu-
ally lower than twofold) down-regulation of miRNA tar-
gets.16 Although the proteins with decreased abundance
are potential targets of miRNA, their abundance is influ-
enced by additional factors, such as protein turnover.
Thus, studies of the miRNA-perturbed profile of newly
synthesized proteins, by pulsed SIL of amino acid in cell
culture (pulsed SILAC), may provide better quantitation
of targets and more effective miRNA target discovery.16
In the current study, we used the pulsed SILAC technique
to investigate the perturbation of protein synthesis by
overexpression of miR-155 in DLBCL cells. Several tar-
gets of miR-155, such as WEE1, SHIP1, and PIK3R1
(p85), were identified from the proteomics study. Func-
tional studies indicated that the phosphatidylinositol 3-ki-
nase (PI3K)–AKT pathway was constitutively activated by
miR-155 overexpression in DLBCL.
Materials and Methods
DLBCL Cell Lines and Patient Samples
Four DLBCL cell lines, SU-DHL6, SU-DHL16 (hereafter,
DHL16), OCI-Ly3, and OCI-Ly10, were used. SU-DHL6
and DHL16 are DLBCL lines with GCB GEP, whereas
OCI-Ly3 and OCI-Ly10 are DLBCL lines with ABC
GEP.12,17 These cells were cultured in 90% RPMI 1640
medium with 10% fetal bovine serum, except that OCI-
Ly3 used 90% Iscove’s modified medium and OCI-Ly10
used 10% human serum.
Primary frozen tumor samples from 94 patients with de
novo DLBCL who were treated with rituximab plus stan-
dard doxorubicin, cyclophosphamide, vincristine, and
prednisone (CHOP) or CHOP-like therapy were retrieved
from the Nebraska Lymphoma Study Group. The GEP
information of 65 tumors was obtained by using the HG
U133 Plus2 GeneChip following standard protocols (Af-
fymetrix, Inc., Santa Clara, CA), as previously published
(part of the Lymphoma/Leukemia Molecular Profiling Proj-
ect consortium).18 These patients were subclassified as
having either the GCB or ABC type of DLBCL by their
GEP information. Total RNA extracts from 67 of the pa-
tient tumor samples and four DLBCL lines were collectedfor miR-155 profiling. This study was approved by the
Institutional Review Board of the University of Nebraska
Medical Center, Omaha.
Construction of miR-155 Plasmid and
Transfection
A BIC DNA fragment (669 bp) containing the miR-155
sequence was amplified from human genomic DNA. The
primers used to clone miR-155 were as follows: forward,
5=-GATCAAAGTCTTCAAATATGCCTAAAGG-3=; and re-
verse, 5=-TGAACAAGCCAAAACCTGC-3=. The miR-155
DNA fragment was cloned downstream of green fluores-
cent protein (GFP) in an enhanced GFP (EGFP)–C2 vec-
tor, and the construct was confirmed by restrictive diges-
tion and DNA sequencing. DHL16 cells were transiently
transfected with this miR-155 expression construct
(EGFP–miR-155) or control vector (EGFP-Ctrl) using the
pmaxFP expression system (Amaxa, Gaithersburg, MD)
with buffer V and program L29.19 Transfection efficiency
was evaluated by GFP expression and measured by real-
time PCR.
SILAC Sample Preparation and SCX-NanoLC-
MS/MS Analysis
Pulsed SILAC was used for quantitative proteomics anal-
ysis. For heavy labeling medium, L-[13C6]-lysine was
used (Pierce Biotechnology, Rockford, IL); and for the
light condition, L-[12C6]-lysine was used. DHL16 cells
were cultured in normal RPMI 1640 medium, and tran-
sient transfection was performed. The cells were allowed
to recover for 5 hours after transfection. Then, the cells
transfected with miR-155 vector were cultured in the
SILAC light medium, whereas the cells transfected with
control vector were cultured in the SILAC heavy medium.
Both cells were cultured in SILAC media for another 9
hours, and harvested separately in 8 mol/L urea lysis
buffer. Then, based on their total protein abundances,
equal masses of heavy and light lysates were mixed and
tryptic digested, as previously described.20
Strong cation exchange (SCX) chromatography was
performed on an Ultimate 3000 HPLC system (Dionex,
Sunnyvale, CA), whereas the nanoLC-MS/MS analysis
was performed using a NanoLC-2D LC system (Eksigent,
Dublin, CA) and an linear ion trap (LTQ)-Orbitrap-XL
mass spectrometer equipped with a nanospray ionization
source (Thermo Scientific, San Jose, CA), as previously
described.20 Briefly, the mixture of tryptic peptides was
separated by SCX into 20 fractions, and each fraction
was analyzed by nanoLC-MS/MS. Survey full-scan MS
spectra (from m/z 375 to 1575) were acquired in the
Orbitrap with resolution r  100,000. LTQ MS was oper-
ated in a data-dependent mode to automatically switch
between the MS and MS/MS acquisitions. The most in-
tense ions (top five) were sequentially isolated for frag-
mentation using collision-induced dissociation with a nor-
malized collision energy of 30% and a target value of
5000.
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MS raw data were deisotoped and converted to the mgf
files,20 then submitted to the Mascot (Matrix Science,
London, UK) search engine for peptide identification
against the human international protein index database
(version 3.52) with the decoy database technique. Carb-
amidomethylation of cysteine was used as a fixed mod-
ification, and oxidation of methionine was used as a vari-
able modification. The initial mass deviation tolerance of
precursor ion was set to 20 ppm, and the fragment ion
tolerance was set to 0.5 Da. A maximum of two missed
cleavages was allowed in peptide identification.
After the database search, the resulting dat files and
MS raw data were imported into the UNiquant software
for protein quantitation.20 All spectra of identified pep-
tides with a Mascot score 10 were quantified to ob-
tained the intensities of the heavy and light counterpart. A
cutoff of signal/noise ratio higher than two was applied to
remove the low-confidence peaks. Then, a criterion,
termed quality of peptide identification,20 based on the
Mascot score and mass accuracy of the precursor, was
used to filter the quantified peptides and proteins, respec-
tively, using a false discovery rate 0.01. Finally, locally
weighted scatterplot smoothing (Lowess) method21 was
used to normalize the heavy/light ratios of quantified pro-
teins, using the sum of intensities for the heavy species
divided by the light species for each protein.
Knockdown of p85 by siRNA
Small-interfering RNAs (siRNAs) that specifically inhibit
p85 (ON-TARGETplus SMARTpoll siRNA and ON-
TARGETplus Non-targeting pool) were obtained from
Dharmacon Inc. (Chicago, IL). One million DHL16 cells
were transfected with either 0.2 nmol/L p85 siRNA or
control siRNA using the pmaxFP expression system.
Cells were harvested 24 hours after treatment.
Transduction of DHL16 and OCI-Ly3 Cells
The tetracycline-regulated retroviral vector TMP (OpenBio-
System, Huntsville, AL) was modified by deleting miR-30
sequences. The miR-155 sequence was cloned into this
retrovirus vector (with Tet-On regulation system), following a
protocol as previously described.22 This retrovirus vector
was named pTIP-miR-155 and transduced into DHL16 cells
to establish a B-cell line with sustained expression of miR-
155. The pTIP-GFP vector (without miR-155) was trans-
duced into DHL16 cells as a negative control.
Construction of the pTIP-miR-155-sponge vector fol-
lows the protocol described by Sharp and coworkers.23
The microRNA sponge plasmid and the control vector
were initially obtained from the laboratory of Sharp and
coworkers, and modified to competitively inhibit miR-155.
Briefly, oligonucleotides containing miR-155 binding sites
with four-nucleotide spacers to provide a central bulge
were annealed, self-ligated, gel purified, and cloned into
pcDNA5-CMV-d2eGFP vector (Invitrogen, Carlsbad,
CA). Subclones containing 11 tandem copies of the
sponge sites were identified and confirmed by sequenc-ing, and then inserted into the pTIP-GFP vector (down-
stream of GFP). OCI-Ly3 cells were transduced with the
pTIP-miR-155-sponge vector to establish a B-cell line
with sustained inhibition of miR-155. All transduced cells
were positively selected by puromycin for 2 weeks and
evaluated for GFP expression.
RT-qPCR
For quantitative RT-PCR (RT-qPCR), miR-155 expression
was measured by the real-time qPCR-based TaqMan
human microRNA assay from Applied Biosystems (Foster
City, CA), according to the standard protocol. RNA was
isolated using the mirVana miRNA Isolation Kit (Ambion,
Austin, TX) and reverse transcribed with both miR-155
and U6 primers. The data set was normalized using the
average expression of U6 small-nuclear RNA.
To evaluate mRNA expression, total RNA was ex-
tracted using TRIzol reagent, and 1 g of total RNA from
patient samples was used for RT (Invitrogen). Primers
used were as follows: p85, 5=-GCTGAGAAAGAC-
GAGAGACC-3= (forward) and 5=-TTCATCATCTTCCAC-
CAGTG-3= (reverse); and glyceraldehyde-3-phosphate
dehydrogenase, 5=-CGACCACTTTGTCAAGCTCA-3= (for-
ward) and 5=-CCCTGTTGCTGTAGCCAAAT-3= (reverse).
Two replicates were included for each measurement.
Luciferase Activity Assay
Sequences of the 3=-UTR of human p85 gene (human
PIK3R1, NM_181504) were cloned with the following
primers: forward, 5=-GTCCTACTGATGTTCCTTTGG-3=;
reverse, 5=-AACTGACCGTGACATCCTC-3=; and mutation,
5=-GTCACCATGAGATAGATCTAGCTGCCCAGGATG-3=
(mutated sites italicized). The DNA insert was introduced
downstream of the luciferase reporter gene in the pGL3
promoter vector (Promega, Madison, WI). Luciferase activ-
ity assays were performed with the Dual-Luciferase Re-
porter System (Promega). HEK-293T cells were cotrans-
fected with luciferase reporter plasmids (250 ng) and
miR-155 expression vector (750 ng). Luciferase activities
were measured 48 hours after transfection.
Cell Viability Assay
Transduced DHL16 and OCI-Ly3 cells were plated at a
density of 10,000 cells per well into a six-well plate. Cell
proliferation was examined at 0, 1, 2, 4, and 6 days after
seeding. Doxycycline (1 g/mL) was added every other
day. Culture medium, 100 L, was added together with
20 L of Cell Titer 96AQueousOne solution (Promega)
and then incubated at 37°C for 2 hours (three replicates).
Optical density was measured at 490 nm using a plate
reader.
Western Blot Analysis
Preparation of cell lysates and Western blot analysis were
performed as previously described.19 Primary antibodies
included the following: p85 (Genscript, Piscataway, NJ),
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phatase 1 (SHIP1; Santa Cruz Biotechnology, Santa Cruz,
CA), phosphorylated glycogen synthetase kinase 3 (Ser9;
Signalway Antibody, Pearland, TX), phosphorylated AKT
(Ser473), phosphorylated AKT (Thr308), and AKT (Cell Sig-
naling, Danvers, MA).
Results
Expression of BIC Transcripts and miR-155 in
Patients with DLBCL
We examined the expression levels of BIC, the miR-155
precursor transcript, in patients with DLBLC. The average
BIC expression in 41 patients with GCB-DLBCL and 24
patients with ABC-DLBCL was calculated from GEP data.
As shown in Figure 1A, the ABC subgroup cases had a
significantly higher (P  6.24E-07) expression of BIC
transcripts than the GCB subgroup.
Next, we studied the basal expression of mature miR-
155 by RT-qPCR in two GCB-DLBCL lines (SU-DHL6 and
DHL16), two ABC-DLBCL cells (OCI-Ly3 and OCI-Ly10),
and the frozen tumor samples of 36 patients with GCB-
DLBCL and 31 patients with ABC-DLBCL. The ABC sub-
group of cases had a significantly higher (P  6.86E-05)
expression of mature miR-155 than the GCB subgroup
(Figure 1B). Two GCB-DLBCL lines (SU-DHL6 and
DHL16) had lower expression of miR-155 compared with
the two ABC-DLBCL lines (OCI-Ly3 and OCI-Ly10). Our
data indicated that the ABC-DLBCL subgroup was sig-
nificantly more likely to overexpress miR-155 compared
with the GCB-DLBCL subgroup.
Quantitative Proteomics Reveals Potential
Targets of miR-155
Because DHL16 cells had a relatively low expression of
miR-155, we overexpressed miR-155 in DHL16 cells by
transient transfection. RT-qPCR indicated that approxi-
Figure 1. miR-155 expression (exp.) in patients with DLBCL and cell lines.
A: Expression of BIC/MIR155HG transcripts in patients with ABC-DLBCL
(n  24) and GCB-DLBCL (n  42). Expression based on GEP analysis is
shown in a box-and-whiskers plot (5th and 95th percentiles). B: Expression
of mature miR-155 detected by RT-qPCR in four DLBLC cell lines (OCI-Ly3,
OCI-Ly10, SU-DHL6, and DHL16), patients with ABC-DLBCL (n  31), and
patients with GCB-DLBCL (n  30). All miR-155 expression data are normal-
ized to the endogenous U6 RNA expression level by the following formula:
CT CT(U6) CT(miR-155). GraphPad Prism software version 5.0 (La Jolla,
CA) is used to analyze and visualize the expression data.mately 1000-fold overexpression of miR-155 was obtained
in cells with EGFP-miR-155 transfection compared with the
EGFP-Ctrl group (see Supplemental Figure S1 at http://
ajp.amjpathol.org). LC-MS/MS–based quantitative pro-
teomics with pulsed SILAC labeling was performed to
study the impact of miR-155 overexpression on protein
output. As illustrated in Figure 2A, newly synthesized
proteins were labeled for 9 hours by SILAC heavy
medium, beginning 5 hours after transfection in the
EGFP-Ctrl cells. Cells in the EGFP–miR-155 groups
were similarly kept in SILAC light medium for 9 hours.
Equal masses of heavy and light cell lysates were
mixed, digested, and analyzed by LC-MS/MS. By using
Mascot for peptide identification and UNiquant for pep-
tide and protein quantification,20 a total of 2103 proteins
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Figure 2. Quantitative proteomics for discovering miR-155 targets. A: Work
flow of the proteomics strategy with pulsed SILAC labeling. DHL16 cells are
transiently transfected with either EGFP-miR-155 or EGFP-Ctrl plasmid. Cul-
ture medium is changed 5 hours after transfection, and cells are harvested 9
hours later. Then, the cell lysates are mixed at equal protein masses and
subjected to tryptic digestion, SCX fractionation, and LC-LTQ-Orbitrap anal-
ysis. Peptides are identified by Mascot, and proteins are quantified by UNi-
quant. B: Response of protein synthesis to altered miR-155. Cumulative
distributions of different seed classes for the quantified proteins are plotted.
Matches of miR-155 and 3=-UTR of mRNA are as follows: positions 1-8
(3=-UTR 8mer), 2–8 (3=-UTR 7mer-8), 2–7 with adenosine in position 1
(3=-UTR 7mer-A1), and 2–7 (3=-UTR 6mer).were quantified from 6569 unique peptides, with a false-
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http://ajp.amjpathol.org). We used the Lowess method24
to normalize the quantified ratios of proteins, by assum-
ing that the rate of synthesis of most proteins was not
changed by miR-155 treatment (see Supplemental Figure
S2A at http://ajp.amjpathol.org). After Lowess normaliza-
tion, heavy/light (H/L) ratios of quantified proteins fol-
lowed a gaussian-like distribution (see Supplemental Fig-
ure S2B at http://ajp.amjpathol.org). In our proteomics
study, proteins with high H/L ratios were the proteins
whose synthesis was repressed by miR-155 overexpres-
sion. Because miRNAs may target mRNAs primarily by
binding to seed sequences in the 3=-UTRs, we searched
the National Center for Biotechnology Information RefSeq
database of human transcripts to identify the 3=-UTR
sequence motifs that miR-155 can potentially target. Dif-
ferent seed classes for miR-155 were generated by
matching to positions 1–8 (3=-UTR 8mer), 2–8 (3=-UTR
7mer-m8), 2–7 with adenosine in position 1 (3=-UTR
7mer-1A), and 2–7 (3=-UTR 6mer), according to the algo-
rithm of TargetScan.25 Of the proteins containing 3=-UTR
8mer or 3=-UTR 7mer-m8 seeds, 21 were up-regulated by
1.25-fold (H/L 0.8), whereas 34 were inhibited by
1.25-fold (H/L 1.25). For proteins without miR-155
seeds, 453 were up-regulated, whereas 259 were down-
regulated, by 1.25-fold. Proteins with miR-155 seeds
were significantly enriched in the down-regulated pro-
teins after miR-155 transfection (Fisher’s exact test, P 
0.0003). The cumulative frequency curves for the 3=-UTR
8mer and 3=-UTR 7mer-m8 groups showed a rightward
shift compared with the other groups in the right part of
Figure 2B, indicating that the effect of miR-155 on the
cumulative curves was mainly through the inhibition of the
proteins, with down-regulation by miR-155 transfection.
Conservation of the miR-155 binding sequence was
another important factor in predicting the repressive ef-
fect on miR-155 targets.25 Ten proteins (WEE1, FXR1,
PEA15, GATAD2B, CAB39, PIK3R1, DNAJB1, CHAFIA,
INPP5D, and LSM14A) showed both conserved seed
sequences in their 3=-UTR and repressed protein produc-
tion (see Supplemental Table S2 at http://ajp.amjpathol.
org). All these proteins contained the 3=-UTR 8mer or
3=-UTR 7mer-m8 type of miR-155 seed, which were the
two most stable seed sequences. WEE1 (WEE1 ho-
molog–Schizosaccharomyces pombe), a cell-cycle regu-
lator, was quantified, with an H/L ratio of 3.52. It was
previously reported that overexpression of miR-155 en-
hanced the mutation rate and decreased the efficiency of
DNA checkpoint mechanisms by targeting WEE1 in inflam-
mation and cancers.26 Quantitative proteomics also identi-
fied two negative regulators of the PI3K-AKT pathway,
INPP5D (SHIP1) and PIK3R1 (P85), both of which were
down-regulated by miR-155 and contained conserved
binding sites for miR-155 (see Supplemental Table S2 at
http://ajp.amjpathol.org). MS-based identification and quan-
tification of these two proteins are illustrated in Supplemen-
tal Figure S3 (available at http://ajp.amjpathol.org). SHIP1
was identified as a direct target of miR-155 in previous
studies.27 P85, a novel target of miR-155, was a regu-
latory subunit of PI3K, with dual activation and repressiveroles. Binding of p85 by activated receptor tyrosine
kinases or adaptor proteins relieved the basal repression
of p110, the catalytic subunit of PI3K, leading to the
activation of AKT.28
P85 Is a Direct Target of miR-155
The 3=-UTR of p85 contained a predicted binding site for
miR-155, which was conserved among several species,
including human, mouse, rabbit, and dog (Figure 3A). To
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Figure 3. miR-155 activates the PI3K-AKT signaling pathway by targeting
p85. A: Schematic layout of the p85 mRNA (NM_181504). The predicted
miR-155 binding site is indicated. This binding site is conserved within the
p85 3=-UTR from different species. A fragment of the p85 3=-UTR (nucle-
otides 5636 to 6276, which contain the miR-155 seed site) is cloned to
downstream of luciferase report vector, and a construct containing a muta-
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containing the 3=-UTR of WT p85 or with point mutations (MUTs) in the
miR-155 binding site are cotransfected with either EGFP-miR-155 or EGFP-
Ctrl vectors in HEK-293T cells. Data are shown as mean  SD of luciferase
activity (three replicates). C: Relative expressions of p85mRNA in DHL16 cells
transfected with either EGFP-miR-155 or EGFP-Ctrl. D: The PI3K-AKT signaling
pathway is activated by miR-155 in DHL16 cells. P85 and SHIP1 are repressed,
and phosphorylation of AKT (pAKT; Ser473 and Thr308) and glycogen synthe-
tase kinase (GSK) 3 (Ser9) is increased by miR-155 activation.
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interaction with its 3=-UTR, we cloned its 3=-UTR into a
luciferase reporter plasmid. This reporter vector was
cotransfected with either EGFP-C2-miR-155 or EGFP-C2
vector into HEK-293T cells. We observed an approxi-
mately 40% decrease in luciferase activity when 293T
cells were cotransfected with EGFP-miR-155 vector and
luciferase-p85 wild-type (WT) 3=-UTR, compared with
the cells cotransfected with EGFP-Ctrl vector. However,
cotransfection of EGFP-miR-155 failed to repress the lu-
ciferase activity if the p85 3=-UTR contained a mutated
miR-155 seed sequence (Figure 3B). Furthermore, over-
expression of miR-155 repressed p85 mRNA expres-
sion by approximately 50% (Figure 3C) and also re-
pressed p85 protein expression (Figure 3D). By
targeting SHIP1 and p85, the PI3K-AKT pathway was ac-
tivated in DHL16 cells with miR-155 overexpression. West-
ern blot analysis indicated that expression of phosphory-
lated AKT (Ser473 and Thr308) was increased by miR-155
overexpression. Glycogen synthetase kinase 3, a down-
stream effecter protein after AKT activation, also showed
increased phosphorylation at Ser9 (Figure 3D).
Overexpression of miR-155 Activates the
PI3K-AKT Pathway in DLBCL
To determine whether miR-155 can activate the PI3K-AKT
pathway through repressing endogenous p85, we intro-
duced p85-specific siRNA to knock down the expression
of p85. As shown in Figure 4A, DHL16 cells transfected
with anti-p85 siRNA showed decreased expression of
p85. Down-regulation of p85 increased AKT phos-
phorylation compared with DHL16 cells transfected with
control siRNA.
Retroviral vectors containing either the miR-155 con-
struct sequence or the miR-155–specific sponge se-
quence within the 3=-UTR of GFP were used to transduce
DLBCL cells with sustained overexpression or inhibition
of miR-155, respectively (Figure 4B). DHL16, which is a
GCB-DLBCL cell line with low expression of miR-155,
was transduced with pTIP-miR-155 vectors. Ectopic over-
expression of miR-155 up-regulated AKT activity, pre-
sumably by directly targeting p85 (Figure 4B). Next, we
transduced the pTIP-miR-155-sponge retrovirus into OCI-
Ly3 cells, which is an ABC-DLBCL cell line with high
expression of miR-155. Knockdown of miR-155 down-
regulated AKT activity, presumably at least partially by
releasing the repressing effect on p85 (Figure 4B).
Because the effects of AKT activation include in-
creased cell proliferation and inhibition of apoptosis, we
studied cell viability in DHL16 cells with or without sus-
tained overexpression of miR-155. As shown in Figure
4C, DHL16 cells transduced with pTIP-miR-155 have in-
creased cell viability at 4 days. At day 6, the pTIP-miR-
155 group had significantly higher (P  0.05) viability
compared with the pTIP-GFP and WT groups. The cell
viability of OCI-Ly3 cells transduced with the pTIP-miR-
155-sponge was also examined. OCI-Ly3 cells with sus-
tained inhibition of miR-155 exhibited lower (P  0.05)cell viability compared with the other two groups of cells
(Figure 4D).
Discussion
miR-155 has emerged as an important regulator with
impact on tumorigenesis of several types of human lym-
phomas. Our data revealed that patients with ABC-DL-
BCL have significantly higher expression of miR-155
compared with the GCB subtype. By using the pulsed
SILAC technique, we determined that several key regu-
lators, such as WEE1, SHIP1, and p85, were regulated
by miR-155. Functional analysis indicated that AKT ac-
tivity in DLBCL was regulated by miR-155 through direct
targeting of p85, a positive and negative regulator of the
PI3K-AKT pathway. Although p85 stabilizes p110 and
recruits it to activated surface receptors, it inhibits its
activity in the absence of stimulation. In addition, in many
cell types, p85 is in stoichiometric excess, and the free
subunit can compete with the p85-p110 heterodimer for
Figure 4. Constitutively overexpressing miR-155 activates PI3K-AKT signal-
ing and increases cell viability. A: Knockdown of p85 by siRNA decreases
the phosphorylation (Ser473 and Thr308) of AKT in DHL16 cells. B: Use of
the retroviral vector with a Tet-On regulation system (pTIP-GFP). Either
miR-155 DNA constructs (pTIP-miR-155) or an miR-155 sponge sequence
with 11 tandem repeats of the miR-155 binding site (pTIP-miR-155-sponge) is
cloned downstream of GFP. Transduction of DHL16 cells with pTIP-miR-155
increases AKT phosphorylation (pAKT; Ser473 and Thr308), and transduction
of OCI-Ly3 cells with pTIP-miR-155-sponge decreases phosphorylation
(Ser473) of AKT. C: Cell viability of WT DHL16 cells or cells transduced with
pTIP-GFP or pTIP-miR1-155 vectors. *P  0.05 compared with untransduced
or pTIP-GFP–transduced cells.D: Cell viability of untransduced OCI-Ly3 cells
or cells transduced with pTIP-GFP or pTIP-miR1-155-sponge vectors. *P 
0.05 compared with untransduced or pTIP-GFP–transduced cells. Data are
shown as mean  SD (three replicates).receptor binding.29
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PI3K-AKT pathway is a prognostic marker in DLBCL. The
oncogenic effects of AKT in DLBCL are numerous, in-
cluding, among others, activation of mammalian target of
rapamycin signaling31; increased glucose metabolism,
which promotes MCL1 synthesis and resistance to BCL2
inhibition32; and inhibition of apoptosis through expres-
sion of XIAP.33 GEP analysis of DLBCL indicated that
ABC-DLBCLs generally exhibit high NF-B activity,
whereas GCB-DLBCLs express high levels of prolifera-
tion- and metabolism-related genes.12 AKT activity is es-
sential for survival of some, but not all, DLBCL cell lines of
both subtypes, but it may be regulated differently in the
two. In the ABC subtype, NF-B activation plays an im-
portant role for tumor survival34; part of its effect may be
through the induction of miR-155 in this subtype, contrib-
uting to constitutive AKT activity and inhibition of cell
death.
Aberrant overexpression of miRNAs activates PI3K-
AKT signaling by down-regulation of its suppressors
(eg, repressing PTEN by miR-21 and miR-17-92).35
SHIP1, another negative regulator of the PI3K-AKT
pathway, was previously identified as a direct target of
miR-155.27 PI3K and PTEN antagonistically control sig-
naling from phosphatidylinositol (3,4,5)-trisphosphate
(PIP3) to AKT phosphorylation and activation. A role of
PTEN and PI3K in tumorigenesis is supported by the
observation that somatic mutations of these proteins
occur frequently and result in constitutive activation of
AKT in human cancers.36 Our data indicated that p85,
the PI3K regulatory subunit, was directly repressed by
miR-155. Overexpression of miR-155 activates the
PI3K-AKT signaling pathway, which is likely, at least in
part, through down-regulation of p85. Furthermore,
our data demonstrated that gain of function for miR-
155 in a GCB cell line with low miR-155 expression
activates AKT and, hence, increases cell viability,
whereas, conversely, down-regulation of miR-155 di-
minishes AKT activity and decreases cell viability in an
ABC cell line with high expression of miR-155. More-
over, normal function of PTEN requires p85 binding at
its N-terminal SH3 domain to enhance PTEN lipid phos-
phatase activity.28,29 Considering the central role of
PTEN activity in regulating AKT phosphorylation, inhi-
bition of p85 by miR-155 may have dual functions:
abrogating p110-inhibitory activity and preventing the
recruitment of PTEN, both resulting in the enhancement
of AKT signaling.
In summary, our study revealed a novel molecular
mechanism by which miR-155, through direct targeting
and repressing p85, activates oncogenetic AKT signal-
ing in DLBCL.
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